← Back to Team

Charles Dunn

Vice President

Charles dunn banner

Charles joined SV in 2018 and is a Senior Associate in the biotech team. He helps form and fund companies developing transformational new medicines, with a broad focus from new company creation to later stage opportunities. Charles serves as a board observer at Autifony Therapeutics, EnaraBio, Pulmocide, Imbria Therapeutics,and Mestag Therapeutics which he also helped incubate and launch.

Charles identifies and evaluates new opportunities and advises portfolio company management on strategy, fundraising, and business development.

Prior to joining SV, Charles qualified as an ACA after three years at Deloitte, with a focus on Life Sciences clients including SV portfolio companies.

Outside of SV, Charles is a keen chef, swimmer, and traveller.

Academic Credentials:
MSci Human Genetics, University College London; specialization in the genetics of neurodegenerative disease and cancer biology. Chartered accountant (ACA).

Investing in Women Code Logo

We invest in talented innovators. We strongly adhere to the view that diversity, including under-represented groups, strongly adds to success. If you are an entrepreneur seeking investment and a partner who can help you to build your business, we would love to hear from you. Please get in contact with our team.